Horning et al. demonstrated that in patients with biochemical recurrence following radical prostatectomy, the plasma cfDNA methylation of SRD5A2 and CYP11A1 was elevated, indicating that cfDNA may be useful in detecting prostate cancer recurrence [67]. Here, CYP11A1 is linked to prostate carcinoma.